Tildrakizumab Every 12 Weeks Fits Shift Workers; Panel Weighs Scalp and Nail Data
Panelists review scalp- and nail-specific efficacy data for tildrakizumab, secukinumab and ustekinumab, plus a monitoring playbook for breakthrough symptoms and biosimilar switching.